PTX3 and metabolic dysfunction-associated steatohepatitis: In a middle-aged population, plasma PTX-3 levels above 2.45 ng/mL were found to effectively discriminate between patients with NASH and those without, with 91.1% sensitivity and 71.4% specificity.